Implications and prognostic value of K-ras mutation for early-stage lung cancer in women

Journal of the National Cancer Institute

Volumn 91, Issue 23, 1999, Pages 2032-2038

  Nelson, Heather H ^a   Christiani, David C ^b   Mark, Eugene J ^d   Wiencke, John K ^c   Wain, John C ^d   Kelsey, Karl T ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Bldg 1 ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER INVASION; CANCER STAGING; CANCER SURVIVAL; DISEASE MARKER; FEMALE; GENE MUTATION; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE RAS; PRIORITY JOURNAL; PROGNOSIS;

EID: 0033485503     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.23.2032     Document Type: Article

References (52)

1. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, Heath CW Jr. Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 1997;89:1580-6.
2. Lubin JH, Blot WJ. Assessment of lung cancer risk factors by histologic category. J Natl Cancer Inst 1984;73:383-9.
3. Brownson RC, Chang JC, Davis JR, Gender and histologic type variations in smoking-related risk of lung cancer. Epidemiology 1992;3:61-4.
4. Travis WD, Travis LB, Devesa SS. Lung Cancer [published erratum appears in Cancer 1995; 75:2979]. Cancer 1995;75(1 Suppl): 191-202.
5. Wynder EL, Hoffmann D. Smoking and lung cancer: scientific challenges and opportunities. Cancer Res 1994;54:5284-95.
6. Parkin DM, Sasco AJ. Lung cancer: worldwide variation in occurrence and proportion attributable to tobacco use. Lung Cancer 1993;9: 1-16.
7. Peto R, Lopez, AD, Boreham J, Thun M, Heath C Jr, Doll R. Mortality from smoking worldwide. Br Med Bull 1996;52:12-21.
8. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst 1996;88: 183-92.
9. McDuffie HH, Klaassen DJ, Dosman JA. Female-male differences in patients with primary lung cancer. Cancer 1987;59:1825-30.
10. McDuffie HH, Klaassen DJ, Dosman JA. Men, women and primary lung cancer - a Saskatchewan personal interview study. J Clin Epidemiol 1991;44:537-44.
11. Zang EA, Wynder EL. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarrette smokers. Cancer 1992; 70:69-76.
12. Risch HA, Howe GR, Jain M, Burch JD, Holowaty EJ, Miller AB. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993;138:218-93.
13. Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993;54:44-8.
14. Barbacid M. Ras genes. Annu Rev Biochem 1987;56:779-827.
15. Bos, JL. p21ras: an oncoprotein functioning in growth factor-induced signal transduction. Eur J Cancer 1995;31A:1051-4.
16. Khosravi-Far RS, Solski PA, Clark GJ, Kinch MS, Der CJ. Activation of Racl, RhoA, and mitogen-activated protein kinases is required for Ras transformation. Mol Cell Biol 1995;15: 6443-53.
17. Qiu RG, Chen J, Kirn D, McCormick F, Symons M. An essential role for Rac in Ras transformation. Nature 1995;74:457-9.
18. Hughes PE, Renshaw MW, Pfaff M, Forsyth J, Keivens VM, Schwartz, MA, et al. Suppression of integrin activation: a novel function of a Ras/Raf-initiated MAP kinase pathway. Cell 1997;88:521-30.
19. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323: 561-5.
20. Rosell R, Li S, Skacel Z, Mate JL, Maestre J, Canela M, et al. Prognostic impact of mutated K-ras gene in surgically resected non-small cell lung cancer patients. Oncogene 1993;8: 2407-12.
21. Rosell R, Monzo M, Molina F, Martinez E, Pifarre A, Moreno I, et al. K-ras genotypes and prognosis in non-small-cell lung cancer. Ann Oncol 1995;6 Suppl 3:S15-20.
22. Silini EM, Bosi F, Pellegata NS, Volpato G, Romano A, Nazari S, et al. K-ras gene mutations: an unfavorable prognostic marker in stage I lung adenocarcinoma. Virchows Arch 1994;424:367-73.
23. Fukuyama Y, Mitsudomi T, Sugio K, Ishida T, Akazawa K, Sugimachi K. K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. Br J Cancer 1997;75:1125-30.
24. Cho JY, Kim JH, Lee YH, Chung KY, Kim SK, Gong SJ, et al. Correlation between K-ras gene mutation and prognosis of patients with nonsmall cell lung carcinoma. Cancer 1997;79: 462-7.
25. nd, Shieh DB, Richards W, et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-77.
26. De Gregorio L, Manenti G, Incarbone M, Pilotti S, Pastorino U, Pierotti MA, et al. Prognostic value of loss of heterozygosity and KRAS2 mutations in lung adenocarcinoma. Int J Cancer 1998;79:269-72.
27. Sugio K, Ishida T, Yokoyama H, Inoue T, Sugimachi K, Sasazuki T. ras gene mutations as a prognostic marker in adenocarcinoma of the human lung without lymph node metastasis. Cancer Res 1992;52:2903-6.
28. Kern JA, Slebos RJ, Top B, Rodenhuis S, Lager D, Robinson RA, et al. C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. J Clin Invest 1994;93: 516-20.
29. Isobe T, Hiyama K, Yoshida Y, Fujiwara Y, Yamakido M. Prognostic significance of p53 and ras gene abnormalities in lung adenocarcinoma patients with stage I disease after curative resection. Jpn J Cancer Res 1994;85: 1240-6.
30. Keohavong P, DeMichele MA, Melacrinos AC, Landreneau RJ, Weyant RJ, Siegfried JM. Detection of K-ras mutations in lung carcinomas: relationship to prognosis. Clin Cancer Res 1996;2:411-8.
31. Keohavong P, Zhu D, Melacrinos AC, DeMichele MA, Weyant RJ, Luketich JD, et al. Detection of low-fraction K-ras mutations in primary lung tumor using a sensitive method, Int J Cancer 1997;74:162-70.
32. Siegfried JM, Gillespie AT, Mera R, Casey TJ, Keohavong P, Testa JR, et al. Prognostic value of specific KRAS mutations in lung adenocarcinomas. Cancer Epidemiol Biomarkers Prev 1997;6:841-7.
33. Greatens TM, Niehans GA, Rubins JB, Jessurun J, Kratzke RA, Maddaus MA, et al. Do molecular markers predict survival in nonsmall-cell lung cancer? Am J Respir Crit Care Med 1998;157:1093-7.
34. Nemunaitis J, Klemow S, Tong A, Courtney A, Johnston W, Mack M, et al. Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung. Am J Clin Oncol 1998;21:155-60.
35. Graziano SL, Gamble GP, Newman NB, Abbott LZ, Rooney M, Mookherjee S, et al. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J Clin Oncol 1999;17:668-75.
36. Lung ML, Wong M, Lam WK, Lau KS, Kwan S, Fu KH, et al. Incidence of ras oncogene activation in lung carcinomas in Hong Kong. Cancer 1992;70:760-3.
37. Slebos RJ, Hruban RH, Dalesio O, Mooi WJ, Offerhaus GJ, Rodenhuis S. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. J Natl Cancer Inst. 1991;83:1024-7.
38. Westra WH, Slebos RJ, Offerhaus GJ, Goodman SN, Evers SG, Kensler TW, et al. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 1993;72:432-8.
39. Husgafvel-Pursiainen K, Hackman P, Ridanpaa M, Anttila S, Karjalainen A, Partanen T, et al. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 1998;53:250-6.
40. Husgafvel-Pursiainen K, Karjalainen A, Kannio A, Anttila S, Partanen T, Ojajarvi A, et al. Lung cancer and past occupational exposure to asbestos. Role of p53 and K-ras mutations. Am J Respir Cell Mol Biol 1999;20:667-74.
41. Nelson HH, Christiani DC, Wiencke JK, Mark EJ, Wain JC, Kelsey KT. K-ras mutations and occupational asbestos exposure in lung adenocarcinoma: asbestos-related cancer without asbestosis. Cancer Res 1999;59:4570-3.
42. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31, 1.
43. Belani CP, Ramanathan RK, Combinedmodality treatment of locally advanced non-small cell lung cancer: incorporation of novel chemotherapeutic agents. Chest 1998;113(1 Suppl):53S-60S.
44. McLoud TC, Bourgouin PM, Greenberg RW, Kosiuk JP, Templeton PA, Shepard JA, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-23.
45. Banerjee SK, Makdisis WF, Weston AP, Mitchell SM, Campbell DR. Microwave-based DNA extraction from paraffin-embedded tissue for PCR amplification. Biotechniques 1995;18: 768-70, 772-3.
46. Mitsudomi T, Viallet J, Mulshine JL, Linnoila RI, Minna JD, Gazdar AF. Mutations of ras genes distinguish a subset of non-small-cell lung cancer cell lines from small-cell lung cancer cell lines. Oncogene 1991;6: 1353-62.
47. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p15INK4a. Cell 1997;88: 593-602.
48. Saunders PT, Maguire SM, Gaughan J, Millar MR. Expression of oestrogen receptor beta (ER beta) in multiple rat tissues visualised by immunohistochemistry. J Endocrinol 1997;154: R13-6.
49. Kato K, Ueoka Y, Kato K, Hachiya T, Nishida J, Wake N. Contribution of enhanced transcriptiortal activation by ER to [12Val] K-Ras mediated NIH3T3 cell transformation. Oncogene 1997;15:3037-46.
50. Caracta CF, Powell C, Brody JS. Estrogen receptor status of lung cancer cell lines [abstract]. Am J Respir Crit Care Med 1999;159: A204.
51. Reddel RR, Ke Y, Kaighn ME, Malan-Shibley L, Lechner JF, Rhim JS, et al. Human bronchial epithelial cells neoplastically transformed by v-Ki-ras: altered response to inducers of terminal squamous differentiation. Oncogene Res 1988;3:401-8.
52. Kinch, MS, Burridge K. Altered adhesions in ras-transformed breast epithelial cells. Biochem Soc Trans 1995;23:446-50.